Altis Labs Raises US$25 Million Series A Co-Led by OrbiMed and Qiming Venture Partners USA to Accelerate Clinical Development with AI Endpoints

TORONTO — Altis Labs, Inc. (“Altis”), the AI endpoint company, today announced the closing of its US$25 million Series A financing. The round was co-led by OrbiMed and Qiming Venture Partners USA, with participation from Innovation Endeavors, Benchstrength, Fusion Fund, Lumira Ventures via the Cancer Breakthrough Fund, and others. The financing will be used to […]